{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:03:07Z","timestamp":1774641787236,"version":"3.50.1"},"reference-count":96,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term maintenance therapy based on inhaled antibiotics may be considered the main strategy for infection control in individuals with CF. While most of the existing evidence is based on infection with Pseudomonas aeruginosa, other important pathogens causing lung inflammation and deterioration exist and should be treated despite the evidence gap. In this chapter, we describe the approaches to the antimicrobial treatment of the most important pathogens in CF and the evidence behind.<\/jats:p>","DOI":"10.1055\/s-0042-1758733","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T01:12:54Z","timestamp":1671498774000},"page":"297-306","source":"Crossref","is-referenced-by-count":2,"title":["Antimicrobial Strategies for Cystic Fibrosis"],"prefix":"10.1055","volume":"44","author":[{"given":"Rikke","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Cystic Fibrosis Center Copenhagen, Rigshospitalet, Copenhagen University, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tacjana","family":"Pressler","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Cystic Fibrosis Center Copenhagen, Rigshospitalet, Copenhagen University, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tavs","family":"Qvist","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Cystic Fibrosis Center Copenhagen, Rigshospitalet, Copenhagen University, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study","volume":"56","author":"D H Andersen","year":"1938","journal-title":"Am J Dis Child"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: a disease with a new face","volume":"109","author":"K De Boeck","year":"2020","journal-title":"Acta Paediatr"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"C Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"ref4","first-page":"1463","article-title":"Concise clinical review managing cystic fibrosis","volume":"183","author":"M C Fibrosis","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/(SICI)1099-0496(199603)21:3<153::AID-PPUL1>3.0.CO;2-R","article-title":"Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment","volume":"21","author":"B Frederiksen","year":"1996","journal-title":"Pediatr Pulmonol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/IDR.S287792","article-title":"Encouraging the development of new antibiotics: are financial incentives the right way forward? A systematic review and case study","volume":"14","author":"I A Dutescu","year":"2021","journal-title":"Infect Drug Resist"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/apm.12689","article-title":"Diagnosis of biofilm infections in cystic fibrosis patients","volume":"125","author":"N H\u00f8iby","year":"2017","journal-title":"APMIS"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus","volume":"16","author":"G D\u00f6ring","year":"2000","journal-title":"Eur Respir J"},{"issue":"07","key":"ref9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"P J Mogayzel Jr","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jcf.2009.04.005","article-title":"Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus","volume":"8","author":"H Heijerman","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"G D\u00f6ring","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"G S Sawicki","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"07","key":"ref13","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/ppul.25942","article-title":"Use of inhaled antibiotics among Danish patients with cystic fibrosis","volume":"57","author":"R M\u00f8ller","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"138","key":"ref14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.rmed.2018.03.034","article-title":"Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: the FREE study","volume":"138","author":"F Blasi","year":"2018","journal-title":"Respir Med"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jcf.2014.04.004","article-title":"Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF)","volume":"13","author":"M J Harrison","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jac\/37.6.1155","article-title":"Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis","volume":"37","author":"M L Barclay","year":"1996","journal-title":"J Antimicrob Chemother"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"2001451","DOI":"10.1183\/13993003.01451-2020","article-title":"Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study","volume":"57","author":"M R Loebinger","year":"2021","journal-title":"Eur Respir J"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/DDDT.S58090","article-title":"Clinical experimentation with aerosol antibiotics: current and future methods of administration [Corrigendum]","volume":"8","author":"P Zarogoulidis","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"J Emerson","year":"2002","journal-title":"Pediatr Pulmonol"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clim.2005.01.013","article-title":"Differential cytokine profile in children with cystic fibrosis","volume":"115","author":"J Brazova","year":"2005","journal-title":"Clin Immunol"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1600-0463.2005.apm_142.x","article-title":"Serum concentrations of GM-CSF and G-CSF correlate with the Th1\/Th2 cytokine response in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"113","author":"C Moser","year":"2005","journal-title":"Acta Pathol Microbiol Scand Suppl"},{"issue":"05","key":"ref24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O","article-title":"Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis","volume":"23","author":"B Frederiksen","year":"1997","journal-title":"Pediatr Pulmonol"},{"issue":"S 01","key":"ref25","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/676882","article-title":"Infection prevention and control guideline for cystic fibrosis: 2013 update","volume":"35","author":"L Saiman","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0140-6736(01)05714-2","article-title":"Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic","volume":"358","author":"A M Jones","year":"2001","journal-title":"Lancet"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/17.4.505","article-title":"An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre","volume":"17","author":"S S Pedersen","year":"1986","journal-title":"J Antimicrob Chemother"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2004.03.008","article-title":"Early intervention and prevention of lung disease in cystic fibrosis: a European consensus","volume":"3","author":"G D\u00f6ring","year":"2004","journal-title":"J Cyst Fibros"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1183\/09031936.05.00009605","article-title":"Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients","volume":"26","author":"G Taccetti","year":"2005","journal-title":"Eur Respir J"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/alr.22953","article-title":"The management of cystic fibrosis chronic rhinosinusitis: an evidenced-based review with recommendations","volume":"12","author":"D B Spielman","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"F Ratjen","year":"2010","journal-title":"Thorax"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment","volume":"338","author":"N H Valerius","year":"1991","journal-title":"Lancet"},{"issue":"S 02","key":"ref33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jcf.2005.05.018","article-title":"Eradication of early Pseudomonas aeruginosa infection","volume":"4","author":"N H\u00f8iby","year":"2005","journal-title":"J Cyst Fibros"},{"issue":"S 02","key":"ref34","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1569-1993(11)60011-8","article-title":"Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report","volume":"10","author":"T Pressler","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ppul.20562","article-title":"Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"42","author":"F Ratjen","year":"2007","journal-title":"Pediatr Pulmonol"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"340","author":"B W Ramsey","year":"1999","journal-title":"N Engl J Med"},{"issue":"24","key":"ref37","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199306173282403","article-title":"Efficacy of aerosolized tobramycin in patients with cystic fibrosis","volume":"328","author":"B W Ramsey","year":"1993","journal-title":"N Engl J Med"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ppul.1950070110","article-title":"Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa","volume":"7","author":"I B MacLusky","year":"1989","journal-title":"Pediatr Pulmonol"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","article-title":"A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis","volume":"20","author":"M E Hodson","year":"2002","journal-title":"Eur Respir J"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jac\/19.6.831","article-title":"Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"19","author":"T Jensen","year":"1987","journal-title":"J Antimicrob Chemother"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"A Schuster","year":"2013","journal-title":"Thorax"},{"issue":"09","key":"ref42","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"K S McCoy","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ppul.21301","article-title":"An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis","volume":"45","author":"C M Oermann","year":"2010","journal-title":"Pediatr Pulmonol"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jcf.2016.01.005","article-title":"Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"15","author":"J S Elborn","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2019.08.001","article-title":"Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis","volume":"19","author":"D Bilton","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1651-2227.1983.tb09789.x","article-title":"Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection","volume":"72","author":"M Szaff","year":"1983","journal-title":"Acta Paediatr Scand"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/49.2.235","article-title":"New antimicrobials in the management of cystic fibrosis","volume":"49","author":"N H\u00f8iby","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"05","key":"ref48","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/thorax.55.5.355","article-title":"Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs","volume":"55","author":"J S Elborn","year":"2000","journal-title":"Thorax"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fphar.2019.00849","article-title":"Antimicrobial treatment of Staphylococcus aureus in patients with cystic fibrosis","volume":"10","author":"S Esposito","year":"2019","journal-title":"Front Pharmacol"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpeds.2008.08.001","article-title":"Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis","volume":"154","author":"S D Sagel","year":"2009","journal-title":"J Pediatr"},{"issue":"05","key":"ref52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/cir399","article-title":"Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis","volume":"53","author":"C Gangell","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"08","key":"ref53","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ppul.23217","article-title":"Risk factors for lung function decline in a large cohort of young cystic fibrosis patients","volume":"50","author":"J Cogen","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.201011-1892OC","article-title":"Infection, inflammation, and lung function decline in infants with cystic fibrosis","volume":"184","author":"N Pillarisetti","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref56","first-page":"CD001912","article-title":"Prophylactic anti-staphylococcal antibiotics for cystic fibrosis","volume":"9","author":"M Rosenfeld","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"07","key":"ref57","first-page":"CD011581","article-title":"Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis","volume":"7","author":"M I Ahmed","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcf.2012.06.005","article-title":"A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF","volume":"12","author":"C S Dalb\u00f8ge","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"10","key":"ref59","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.arbr.2012.07.012","article-title":"Maintenance treatment with inhaled ampicillin in patients with cystic fibrosis and lung infection due to methicillin-sensitive Staphylococcus aureus","volume":"48","author":"L M\u00e1iz","year":"2012","journal-title":"Arch Bronconeumol"},{"issue":"23","key":"ref60","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"E C Dasenbrook","year":"2010","journal-title":"JAMA"},{"issue":"07","key":"ref61","first-page":"CD009650","article-title":"Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis","volume":"7","author":"D KH Lo","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref62","doi-asserted-by":"crossref","first-page":"e0213497","DOI":"10.1371\/journal.pone.0213497","article-title":"Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: a randomized multicenter study","volume":"14","author":"D Dolce","year":"2019","journal-title":"PLoS One"},{"issue":"04","key":"ref63","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/thoraxjnl-2016-208949","article-title":"Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial","volume":"72","author":"M S Muhlebach","year":"2017","journal-title":"Thorax"},{"issue":"03","key":"ref64","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcf.2018.07.005","article-title":"Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis","volume":"18","author":"R Dezube","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"06","key":"ref65","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jcf.2013.04.009","article-title":"Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of 11 patients","volume":"12","author":"E Vanderhelst","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/23120541.00064-2015","article-title":"MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis","volume":"2","author":"E Valli\u00e8res","year":"2016","journal-title":"ERJ Open Res"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhin.2006.10.011","article-title":"Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol","volume":"65","author":"M Macfarlane","year":"2007","journal-title":"J Hosp Infect"},{"issue":"03","key":"ref68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.rmed.2015.01.013","article-title":"Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre","volume":"109","author":"H Hall","year":"2015","journal-title":"Respir Med"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"00614","DOI":"10.1183\/23120541.00614-2020","article-title":"Chronic infection by nontypeable Haemophilus influenzae fuels airway inflammation","volume":"7","author":"F Saliu","year":"2021","journal-title":"ERJ Open Res"},{"issue":"02","key":"ref70","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ppul.21526","article-title":"Lung function decline from adolescence to young adulthood in cystic fibrosis","volume":"47","author":"S L Vandenbranden","year":"2012","journal-title":"Pediatr Pulmonol"},{"issue":"07","key":"ref71","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1513\/AnnalsATS.201402-050AS","article-title":"Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections","volume":"11","author":"J F Chmiel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jcf.2009.10.005","article-title":"Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients","volume":"9","author":"C R Hansen","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"04","key":"ref73","first-page":"CD009876","article-title":"Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis","volume":"4","author":"K H Regan","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jcf.2013.04.013","article-title":"Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis","volume":"12","author":"M Wang","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12890-018-0594-8","article-title":"Implementation of a successful eradication protocol for Burkholderia cepacia complex in cystic fibrosis patients","volume":"18","author":"B A Garcia","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"01","key":"ref77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12890-020-01190-y","article-title":"Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis centres: a pilot study","volume":"20","author":"V Gruzelle","year":"2020","journal-title":"BMC Pulm Med"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcimb.2011.00018","article-title":"Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy?","volume":"1","author":"A Horsley","year":"2011","journal-title":"Front Cell Infect Microbiol"},{"issue":"12","key":"ref79","first-page":"CD013079","article-title":"Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis","volume":"12","author":"F Frost","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref80","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jcf.2013.08.011","article-title":"Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial","volume":"13","author":"D E Tullis","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"11","key":"ref81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01025-20","article-title":"Achromobacter infections and treatment options","volume":"64","author":"B Isler","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"08","key":"ref82","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s10096-011-1182-5","article-title":"Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients","volume":"30","author":"A Lambiase","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jcf.2006.05.011","article-title":"Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance","volume":"6","author":"F De Baets","year":"2007","journal-title":"J Cyst Fibros"},{"issue":"07","key":"ref84","doi-asserted-by":"crossref","first-page":"e1754","DOI":"10.1093\/cid\/ciaa1847","article-title":"Cefiderocol for the treatment of adult and pediatric patients with cystic fibrosis and Achromobacter xylosoxidans infections","volume":"73","author":"N C Warner","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"05","key":"ref85","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1164\/rccm.201009-1392OC","article-title":"Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease","volume":"183","author":"V Waters","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"05","key":"ref86","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2011.03.006","article-title":"Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis","volume":"10","author":"C S Dalb\u00f8ge","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"05","key":"ref87","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1164\/rccm.201010-1668ED","article-title":"Stenotrophomonas maltophilia in cystic fibrosis: guilty or innocent?","volume":"183","author":"A A Colin","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"06","key":"ref88","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/thx.2005.049247","article-title":"Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation","volume":"61","author":"W Chalermskulrat","year":"2006","journal-title":"Thorax"},{"issue":"07","key":"ref89","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1164\/rccm.201307-1200OC","article-title":"Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis","volume":"188","author":"A M Binder","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcf.2014.08.002","article-title":"Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia","volume":"14","author":"T Qvist","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"07","key":"ref91","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1513\/AnnalsATS.201709-727OC","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010-2014","volume":"15","author":"J Adjemian","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"S 01","key":"ref92","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"R A Floto","year":"2016","journal-title":"Thorax"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jcf.2015.09.007","article-title":"Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis","volume":"15","author":"T Qvist","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"02","key":"ref94","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcf.2009.12.001","article-title":"Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis","volume":"9","author":"C R Esther Jr","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"05","key":"ref95","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1183\/13993003.03636-2020","article-title":"Eradication success for non-tuberculous mycobacteria in children with cystic fibrosis","volume":"57","author":"D A Hughes","year":"2021","journal-title":"Eur Respir J"},{"issue":"05","key":"ref96","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/archdischild-2021-322177","article-title":"Treating nontuberculous mycobacteria in children with cystic fibrosis: a multicentre retrospective study","volume":"107","author":"G L Saint","year":"2022","journal-title":"Arch Dis Child"},{"key":"ref97","first-page":"CD010004","article-title":"Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis","volume":"6","author":"V Waters","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"06","key":"ref98","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"K N Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"ref99","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1164\/rccm.201701-0220ED","article-title":"Pseudomonas aeruginosa infection after CFTR restoration. One step back, one step forward","volume":"195","author":"T J Kidd","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"06","key":"ref100","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jcf.2017.06.012","article-title":"The potential of phage therapy in cystic fibrosis: essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways","volume":"16","author":"S Trend","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"01","key":"ref101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4161\/bact.1.1.14942","article-title":"Phages in nature","volume":"1","author":"M RJ Clokie","year":"2011","journal-title":"Bacteriophage"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1758733.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T01:28:31Z","timestamp":1678411711000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1758733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":96,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1758733","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]}}}